Which deal are you thinking of BTB ? I think he is looking in the mirror !
Q
Sanofi ($SNY) intends to follow through with the strategy new CEO Olivier Brandicourt laid out last month, it has some serious dealmaking to do--and on that front, it may soon be bringing in backup. The French drugmaker is close to hiring Morgan Stanley banker Alban de La Sabliere as its new head of M&A, sources told Bloomberg. Currently, he's nearing an agreement with the pharma giant, though the sources cautioned that negotiations aren't final.
It wouldn't be the first recent personnel change among Sanofi's dealmakers. In May, the company hired financial consultant Suresh Kumar to head external affairs and become a member of its exec committee, the news service notes. Also that month, Chief Strategy Officer David-Alexandre Gros, who oversaw business development and M&A, headed for the door, and Sanofi's M&A department has been reporting to CFO Jérôme Contamine ever since. Sources also told the publication in September that Sanofi was working to find a replacement for its M&A VP, Jérôme Delpech.
UNS Price at posting:
14.0¢ Sentiment: Buy Disclosure: Held
